Kevin Appareti – Senior Director, Global Medical Science Liaison
Kevin Appareti is Senior Director, Global Medical Science Liaison in the Chief Medical Office at Royal Philips. He leads the Key Thought Leadership Program and works across Philips’ businesses, markets, and research to build strong internal and external relationships with key thought leaders and influencers. Kevin partners with internal business, market, and research leaders to develop strategic Key Thought Leader (KTL) engagement programs to deliver strategic guidance, leverage clinical and scientific knowledge, foster peer-to-peer relationships, and support clinical and marketing evidence development in support of Philips meaningful innovations.
Prior to the 7 years he has been in the Chief Medical Office, he had 25 years of experience in the Ultrasound Business Unit where he held a variety of leadership positions. He was senior marketing manager of the global luminary program where he contributed to establishing a structured approach to thought leader management. He was also worldwide market development manager and director of product marketing for cardiovascular ultrasound where he brought to market many cardiovascular ultrasound products that set the standard in performance and reliability. He has held additional positions in marketing management for professional services, information technologies and clinical marketing.
He began his academic, research and clinical career as Program Director for Diagnostic Medical Ultrasound Education at the University of Colorado Health Sciences Center where he was involved in clinical research in fetal echocardiography, neonatal brain imaging, and ultrasound technology assessment. He has co-authored many scientific papers, book chapters and presented at numerous international scientific conferences.
He then moved to an industry with various clinical and management roles with Hewlett Packard, Agilent Technologies, and now Royal Philips. Kevin holds a bachelor’s degree in physical science from Colorado State University and an MBA from Boston University and has been an adjunct professor at the University of Massachusetts at Lowell, Manning School of Business.
Kevin is married and has 4 boys. He enjoys basketball, road cycling, tennis and he is an avid photographer.
Jacqueline S. Armani, O.D., F.A.A.O., graduated from the New England College of Optometry, externed at Bascom Palmer and practiced at the VA as a primary care and ocular disease resident optometrist. Jackie has extensive experience training and mentoring residents and students and is a Fellow of the American Academy of Optometry. She joined industry following years of clinical practice as Executive Clinical Outcomes Specialist at Bausch and Lomb. Jackie is now a Medical Science Liaison at Alcon Surgical where she supports over 20 products in 6 product categories. Jackie’s career has included her medical mission in Colombia with VOSH and South Africa with OneSight Global. She resides in New York, volunteers on her alumni board, and loves to travel and plan events.
Senior Director and Head, Global Medical Strategy and Training
Terry Babb – Senior Director and Head, Global Medical Strategy and Training
President- THE DOCTOR'S CHANNEL
Born in New York, Michael grew up in Trumbull, Connecticut. He attended the University of Michigan for undergrad and went on to the University of Connecticut for medical school. After completing his residency in internal medicine at the University of Chicago Hospital in 2002, he left clinical medicine to pursue a career in medical education.
He spent time in the field as an MSL for Pharmacia and Pfizer, before serving as a director for multiple contract MSL teams. Michael serves as a Managing Director of BESTMSLs, a contract MSL organization, where he brings medical and technology expertise to field organizations.
He also serves as the President and Co-Founder of MDea, a creative medical education company in NYC, and The Doctor’s Channel, known as the “educational YouTube for doctors.”
Michael has a passion for technology and gadgets, not to mention his two beautiful daughters. He was selected as one of the “Best Doctors in America” (as voted by his mother, Ilene Banks).
Executive Medical Director
After leaving Egalet, Colville formed a consulting firm, LB United, and joined Innocoll pharmaceuticals as their Executive Medical Director, leading Clinical Development and supporting Medical Affairs activities. He received his medical degree with honors from Howard University and was trained in Internal Medicine at the Hospital of the University of Pennsylvania. After leaving residency he served as Assistant Director at a long-term care facility for the intellectually disabled. In 2010, he joined AlphaBioCom where he served in roles of increasing responsibility to become Director of Clinical and Medical Affairs. Dr. Brown joined Egalet in 2016 where he plays a key role in the development and implementation of Medical Affairs activities.
Director, U.S. Medical Affairs
Ryan Case – Director, U.S. Medical Affairs
Medical Director, Therapeutic Area Head
Joseph Chiao – Medical Director, Therapeutic Area Head
Martin Conner, Pharm.D., MBA
Field Director, Medical Science Liaisons - Women's Health
Stacy Conner – Field Director, Medical Science Liaisons - Women's Health
Dickerson, Ph.D., M.Sc., MBA
Regional Medical Director, Orphan and Rare Diseases
Duke Dickerson – Regional Medical Director, Orphan and Rare Diseases
Distinguished Visiting Practitioner and Adjunct Professor
SETON HALL UNIVERSITY SCHOOL OF LAW
Howard Dorfman – Distinguished Visiting Practitioner and Adjunct Professor
SETON HALL UNIVERSITY SCHOOL OF LAW
Howard L. Dorfman is Founder of H.L. Dorfman Pharmaceutical Consulting, LLC providing compliance, regulatory and risk management consulting services to pharmaceutical and biotech companies and law firms.
His areas of expertise include FDA regulatory law, fraud and abuse, health care compliance, risk management, corporate governance, and litigation.
Mr. Dorfman served as Vice President and General Counsel at Ferring Pharmaceuticals, Inc. in Parsippany, New Jersey where he was responsible for all legal matters relating to the U.S. affiliate of a Swiss-based global pharmaceutical and biotech company. Previously, he served as a Counsel in the Life Sciences group at Ropes & Gray LLP in New York where his practice focused on compliance and regulatory issues relating to the pharmaceutical, biotech, and medical device industries.
Prior to joining Ropes & Gray, Mr. Dorfman was the chief legal officer of the pharmaceutical division of Bayer Healthcare LLC. Before joining Bayer, he was a member of the Bristol-Myers Squibb legal department as Counsel in the Litigation group involved in defense of nationwide product liability litigation and later as Counsel to the US Medicines Group involved in regulatory, compliance and commercial work.
Mr. Dorfman is an adjunct professor at Seton Hall University School of Law and has lectured and published articles on a range of issues including compliance, regulatory and litigation. He is Editor and Contributing Author of the Practising Law Institute Pharmaceutical Compliance and Enforcement Answer Book, now in its fourth edition. He received his B.A. with honors from Yeshiva University and his J.D. degree from Brooklyn Law School.
Dan Hennessy – Vice President, Field Medical Affairs
Dan Hennessy, PhD, MS, MBA, is a VP of Medical Affairs at EMD Serono and has over 18 years track record of significant contributions to medical affairs and clinical development of hematology/oncology and other specialty drug therapies. Specifically, Dr Hennessy has experience in medical affairs, field medical (MSL, Field HEOR) medical communications, pharmaceutical services outsourcing, health economics and outcomes research, clinical development, and regulatory affairs. He has worked on FDA/EAMA submissions and launches in both liquid and solid tumors, non-malignant hematology, Multiple Sclerosis, virology, medical devices, and orphan genetic disorders. As a seasoned industry leader, Dr Hennessy has built medical affairs organizations; and led scientific teams that are responsible for evidence generation, scientific communications, Key Opinion Leader engagement, clinician education, and that capturing and analysis of scientific and competitive insights. Dr. Hennessy’s passion is to leverage medical affairs organizations to accelerate the clinical development process and to facilitate uptake of crucial scientific and medical information to ensure adoption of novel therapeutic interventions into clinical practice. Ensuring that the right patient gets the right drug at the right time is a key driver for Dr. Hennessy.
As Chief Executive Officer of Within3, Lance Hill brings his own brand of energy, leadership and vision to the company.
With the belief that deeper engagement among healthcare professionals results in improved healthcare and better patient outcomes, Lance strategizes with global healthcare decision makers on how to integrate digital collaboration solutions into their businesses as an effective new channel of communication.
Prior to joining Within3, Lance served as the Vice President and General Manager of the worldwide Service Oriented Architecture business unit for the webMethods Corporation, an international leader in enterprise software. With annual revenues exceeding $200 million, webMethods was acquired in 2007 by German giant, Software AG, for $546 million.
Recruited directly from the University of Toledo by tech giant IBM, Lance led the design and implementation of global telecommunication networks for Fortune 500 businesses and major healthcare organizations, as well as consulted and lectured on worldwide technology strategies. He also developed training, methodology and best practices for Global Services consultants. Lance subsequently joined a top 10 U.S. financial services firm where he served as the Vice President of Enterprise Engineering and founded its Fusion Technology Group, dedicated to accelerating corporate adoption of new technologies and business processes.
A veteran in the technology industry, Lance dedicates himself to work he strongly believes in — improving healthcare by providing an easy-to-use, always accessible, digital collaboration solution for healthcare professionals and industry leaders to connect, communicate and collaborate.
Assistant General Counsel, Commercial Brands
David Jacobs – Assistant General Counsel, Commercial Brands
David M. Jacobs has over ten years of experience in the biopharmaceutical industry. He presently serves as Assistant General Counsel, Commercial Brands, at Daiichi Sankyo, Inc. where he supports Global and U.S. clients on a broad array of issues related to the Federal Food, Drug and Cosmetic Act, Foreign Corrupt Practices Act, AntiKickback Act, False Claims Act, HIPAA, advertising and promotion, product labeling, Compliance, State Law and regulatory policy. David also supports the company’s functions responsible for managed markets and key account management, including government price reporting, payer marketing, market access, and the account management relationships with managed care organizations, pharmacy benefit managers, group purchasing organizations and integrated delivery networks. Prior to joining Daiichi Sankyo, David worked for Bristol-Myers Squibb providing general legal and promotion compliance support to the U.S. Sales, Marketing and Medical organizations, as well as the Middle East and Africa. David received his J.D. from Brooklyn Law School and a Masters in Biotechnology from Columbia University.
Randall Kaye, M.D. has over 25 years of pharmaceutical and biotechnology industry experience; he has played key roles leading clinical development and medical affairs at both large pharma and emerging biotech companies. As Chief Medical Officer for Click Therapeutics Dr. Kaye establishes clinical and scientific leadership while providing crucial industry knowledge and insight. He is responsible for for the successful development of the Click’s pipeline while prioritizing scientific integrity and patient-centricity. Dr. Kaye was previously the Chief Scientific Officer for SSI Strategy, where he focused on providing medical and scientific perspectives to the company’s initiatives in medical affairs and clinical development. In conjunction with his role at SSI Strategy, he served as Chief Medical Officer for Axsome Therapeutics. Dr. Kaye formerly served as the Chief Medical Officer of Avanir Pharmaceuticals, Inc. (acquired by Otsuka), where he focused on providing leadership and vision to the clinical development and medical affairs areas while supporting the commercialization of new products from a medical, scientific, regulatory, technical and quality perspective.
Immediately prior to joining Avanir, Dr. Kaye was the Vice President of Medical Affairs for Scios Inc., (acquired by Johnson & Johnson), where he built and integrated a Medical Affairs department consisting of 80 professionals. Dr. Kaye also recruited and managed the Medical Affairs department for InterMune Inc., (acquired by Roche). Prior to joining InterMune, Dr. Kaye served for nearly a decade in a variety of Clinical Development and Medical Affairs positions for Pfizer Inc. Dr. Kaye earned his M.D., M.P.H., and B.S. degrees at George Washington University and was a Research Fellow in Allergy and Immunology at Harvard Medical School.
Matt Lewis – Global Chief Data and Analytics Officer
As Global Chief Data and Analytics Officer at MEDiSTRAVA, Matt is responsible for Medical Insights and Strategic Analytics, which support better decision making through efficient and effective analytics and intelligence applications. From augmented literature searches using AI, to strategies used to identify experts in the offline and digital communities and applications built as Software as a Service, MISA delivers value to stakeholders along the medical, scientific and access pathways continuum. He has doctoral-level training in adult learning principles, health psychology, and instructional design coupled with strong training in qualitative and quantitative methodologies as well as in molecular biology and health services research. Working with clients including 4 of the top 5 and 14 of the top 20, Matt’s team designs studies to evaluate the impact of medical affairs initiatives on clinician learning and performance change and ultimately on patient outcomes.
Vice President, Solution Architecture
Rob Livada – Vice President, Solution Architecture
A graduate of the University of Maryland School of Pharmacy, Baltimore with current licensure to practice in Maryland. Pharmacy career began in community retail operations working in various roles and responsibilities leading up to management. Moved on afterwards to a brief 3-year stint with the Pharmacy Benefits Manager, PCS (CVS Caremark) as a Clinical Specialist analyzing drug utilization and health outcomes in cardiovascular, respiratory, and metabolic diseases.
Began a long tenure in the pharmaceutical industry with Boehringer Ingelheim (BI) working entirely in respiratory medical affairs. Over a 13-year period (2001-2007, and 2009-2016), worked in several roles as Medical Science Liaison (MSL), MSL Manager, and MSL Director. As MSL Director was responsible for building and training BI’s respiratory field base medical team that supported the launches of Spiriva HandiHaler, and the Respimat device related product portfolio for COPD and asthma. Three-time recipient of The President’s Award recognizing exemplary leadership and innovative value-add contributions in Medical Affairs.
Joined The Medical Affairs Company (TMAC) in 2007-2009 as an MSL Program Director and was responsible for designing the operational model for TMAC’s MSL Academy.
An alumnus and member of Ashoka, an international organization promoting social entrepreneurship by empowering individuals as “changemakers”. In 2015, appointed to BI’s Global Executive in Residence International program with Ashoka Brazil. The six-month residency involved designing innovative cost-effective strategies aimed at improving health care delivery services and improving patient outcomes among Saude Crianca’s (Children of Brazil, Rio de Janeiro) asthma population.
Joined Circassia in 2017 as the Respiratory Regional MSL with responsibilities supporting scientific and clinical initiatives related to asthma and COPD.
Favorite activities include family vacations, hiking in the National Parks, photography, golf, wine and food tastings, and college football.
L. Marantz, M.D., Ph.D.
Senior Vice President, Head of Medical Affairs
Jing Marantz – Senior Vice President, Head of Medical Affairs
Jing L. Marantz, MD PhD, joined Alnylam in June 2018 as Senior Vice President, Head of Medical Affairs. Prior to Alnylam, she spent 2 years with Alexion Pharmaceuticals as Vice President, Global Medical Affairs, Complement Franchise as well as Head of U.S. Medical Affairs. Previously, she served as the Global Medical Lead for TECFIDERA, Biogen’s flagship product. Prior to her role at Biogen, Jing was Vice President, Medical Affairs at ARIAD Pharmaceuticals after 11 years at Millennium Pharmaceuticals where she held positions of increasing responsibility in Medical Affairs and Business Development. Jing was previously a management consultant with Strategic Decisions Group and briefly affiliated with Massachusetts General Hospital following a post-doctoral fellowship at the Dana-Farber Cancer Institute. Jing holds an MD from Tongji Medical University, a PhD in Biochemistry and Molecular Biology from Medical University of South Carolina, and an MBA from the University of California at Berkeley.
Pamela Morris currently serves as Key Accounts Director at Komodo Health, a predictive analytics company on a mission to reduce global disease burden through the country’s most actionable healthcare map. She has spent more than 12 years consulting and advising biopharmaceutical companies, including 23 of the top 25 pharmaceutical companies and numerous mid-sized and emerging biotechs, across medical affairs, commercial brand, and market access teams. Pamela specializes in immunology and rare disease, and has also worked extensively with customers across oncology and throughout primary care. At Komodo Health, Pamela focuses on helping her medical affairs customers realize innovative ways to leverage the power of patient-level data in driving strategic decisions for their organizations. She earned her Bachelor of Science in Biological Sciences and Applied Economics & Management from Cornell University, and her MBA from the Haas School of Business at the University of California – Berkeley.
Executive Director, Medical Affairs
Poushali Mukherjea – Executive Director, Medical Affairs
Dr. Poushali Mukherjea has over 18 years of pharmaceutical industry experience in Medical Affairs with core responsibilities in leading global teams in both pre-launch and marketed products in multiple disease areas including CV, diabetes, and chronic kidney disease. She has hands-on experience in developing and implementing a pre-launch medical strategy and plan for a first class product in a competitive disease area. Poushali has led global teams in medical affairs building long-term product strategy, thought leader plans, Lifecycle management/Phase 4 activities, payer and access strategy support, medical communications, publication plans, and advisory board. She has extensive experience in working in complex matrix organizations with co-development and commercialization partners.
Nolan, Ph.D., CMPP
Vice President, Group Scientific Director
Marissa Nolan – Vice President, Group Scientific Director
Immunotherapy Sales Specialist
Marty Perz – Immunotherapy Sales Specialist
Principal Medical Science Liaison
Sandra Petralia – Principal Medical Science Liaison
L. Phillips, M.D.
Vice President and Head of Global Medical Affairs
Terri Phillips – Vice President and Head of Global Medical Affairs
Terri L. Phillips, M.D., joined Merz in January 2018 as Vice President and Head of Global Medical Affairs, providing oversight to the global medical affairs function for the company’s two businesses in medical aesthetics and neurosciences.
Dr. Phillips is widely recognized for her scientific, technical and business innovation expertise and has been in the pharmaceutical industry for more than 16 years. Before joining industry, she practiced full time in Neonatal/Perinatal medicine, serving as Medical Director for a large, multi-site practice in the Washington D.C. metropolitan area. Prior to joining Merz, Dr. Phillips was Vice President of Global Medical Affairs at Santen where she led and built the company’s first global medical affairs function. Her industry experience includes executive leadership roles at Allergan, NPS Pharmaceuticals and as a specialty consultant to emerging medical affairs organizations in numerous therapeutic areas.
Dr. Phillips holds a bachelor’s degree from Bennett College for Women and a doctor of medicine degree from Morehouse School of Medicine in Atlanta. She is dual board certified and completed her Fellowship training in Neonatal/Perinatal medicine. She is a veteran of the United States Army, Medical Corps where she was a recognized leader and the recipient of numerous awards, including the Army Commendation Medal. She has served as author of text and journal articles, is an active community volunteer and has been recognized as one of “America’s Top Pediatricians”.
Dr. Phillips is a member of Merz’s North America Leadership Team.
W. Ravotti, DHSc, PA-C
Senior Associate Director CDMA, Field-Based Medicine Respiratory MSLs
Michael Ravotti – Senior Associate Director CDMA, Field-Based Medicine Respiratory MSLs
Dr. Howard Rutman has served as Vice President and Head of US Medical Affairs for Daiichi Sankyo, Inc. since November 2014. In this role, he leads the Medical Affairs group to enhance access and utilization of Daiichi products through the generation, interpretation and exchange of high quality medical and scientific information valued by multiple stakeholders. Howard has overseen a transition at Daiichi from the cardiovascular-metabolism therapeutic area to an oncology focus.
Howard came to Daiichi as the Executive Medical Director, Thrombosis, leading the medical affairs team for the company’s cardiovascular franchise. He collaborated with research and development colleagues to shape our late-stage pipeline assets for commercialization, including the filing and launch of Savaysa.
Prior to joining Daiichi Sankyo, Howard was the global medical affairs lead at Pfizer for multiple monoclonal antibody biosimilar assets under development across a range of therapeutic areas. Howard also spent a number of years at Taro Pharmaceuticals as group Vice President in Medical Affairs and Clinical Drug Development. Before joining industry, Howard practiced cardiology in a New York-based academic, private practice, with a focus on managing patients with chronic congestive heart failure.
Senior Director and Head, Field Medical Affairs
Sagar Shah – Senior Director and Head, Field Medical Affairs
After receiving his PharmD from Rutgers University School of Pharmacy, Sagar accepted a commercial fellowship role at Johnson & Johnson. Within the Ortho-McNeil division, he led Market Research projects for multiple franchises, and served as Adjunct Faculty at Rutgers. Following his commercial experience, Sagar spent the next few years within a field medical role at Takeda, eventually joining Questcor Pharmaceuticals to find his home within the rare disease space. He transitioned into a leadership role with oversight for the Nephrology & Neurology field medical teams, as well as serving as interim Medical Director. Currently Sagar serves as the Head of Field Medical at Akcea Therapeutics.
Vice President, Medical Affairs
Archie Stone, Ph.D. – Vice President, Medical Affairs
Archie Stone, PhD, is Vice President of Medical Affairs at Alcresta Therapeutics, Inc. Archie has 17 years of experience across the pharmaceutical, medical device and biotechnology industries. His industry expertise covers many different therapies and technology including oral drugs, injectable biologics, and medical devices across many disease states.
He has worked in various executive positions within the Medical Affairs departments of start-ups to mid-size healthcare organizations. Prior to joining Alcresta Therapeutics in 2016, he was the Senior Director of Medical Affairs at Sirtex Medical, Inc where oversaw creation of a patient registry to track outcomes of patient receiving SIR-Spheres therapy to treat inoperable liver tumors. Today that registry has collected clinical and outcomes data on over 1200 patients with liver cancer making it the largest interventional oncology database in the world. He has also been an invited lecturer meetings on managing and training medical science liaisons as well as conducting comparative effectiveness research for different cancer treatment modalities.
Dr Stone earned his Doctorate degree in Biochemistry and Molecular Biology in 2000 at the University of Arkansas for Medical Sciences in Little Rock.
Vice President, Head, Medical Affairs
Beate Stych – Vice President, Head, Medical Affairs
BEATE STYCH, M.D. is the Vice President and Head, Medical Affairs, at Regeneron Pharmaceuticals, Inc. Dr. Stych graduated and received her medical degree from the University of Vienna, Austria, Medical School. She began her pharmaceutical career at Merck & Co. Inc., where she first worked in a medical function in the subsidiary and was soon invited to Headquarters where she held various positions of increasing responsibility in Medical Affairs as well as on the commercial side. After a successful and rewarding career at Merck, Dr. Stych joined NPS Pharmaceuticals to establish a Medical Affairs function in anticipation of the company’s first product launch. In 2007 Dr. Stych accepted the position at Regeneron to newly build a Medical Affairs department and function, ensuring the successful medical introduction of the company’s very first product. Subsequently she structured, grew and shaped the Medical Affairs organization and ensured the successful medical introduction and launch of seven products to date, including the company’s highly successful product in ophthalmology and major advances in medicine in cardiology, dermatology and other immunology related areas. She is now excelling in her leadership of a mature and continuously growing Medical Affairs organization which covers the medical functions of all therapeutic areas in which Regeneron has late-stage development and commercialized products and all functional areas such as Medical Information, Medical Education, field-based Medical Sciences (‘MSLs’), HEOR and medical operations. Her department closely collaborates with colleagues working on earlier stage of product development thus ensuring Medical Affairs support and input for most of the therapeutic areas the company conducts research in.
Arora Sukhatme, Pharm.D.
Head of U.S. Medical Affairs
Monica Sukhatme – Head of U.S. Medical Affairs
J. White, M.D.
Head, U.S. Medical Affairs
Davida White – Head, U.S. Medical Affairs
Medical Director Gastroenterology, U.S. Medical Affairs
Javier Zambrano – Medical Director Gastroenterology, U.S. Medical Affairs
Javier Zambrano is a Medical Executive based in Southern California with over 14 years of experience in Global and US Medical Affairs having led over 10 medical programs; 5 launches and preparing an additional 4 across multiple indications in cardio-cerebrovascular, central nervous system and genetic/metabolic orphan indications. He obtained his Medical Degree at Universidad Católica de Guayaquil and completed his training at University of Miami/Miller School of Medicine.
His career spans large pharmaceuticals, mid-size specialty to small biotech companies brining a practical approach to innovation and overcoming barriers independent of the setting.
Senior Associate General Counsel
Dan Zavodnick currently serves as Regulatory Counsel at Actavis, Inc.. Dan provides proactive legal support to senior management, product brand teams and client groups across the organization, advising and educating on regulations pertaining to branded pharmaceutical products. He serves on multiple brand advertising and promotional review committees, reviewing and analyzing risk-benefit profiles of commercial and medical communications, activities and initiatives. Previously, Dan served as Corporate Counsel at Bayer HealthCare; Head of the U.S. Legal Department of LEO Pharma, Inc.; Regulatory Attorney at Astellas Pharma US, Inc.; Associate Senior Counsel at Eisai Inc.; and Corporate Associate at Cole, Schotz, Meisel, Forman & Leonard, P.A. He is admitted to both the New Jersey and New York bars. Dan received his J.D. from Fordham University School of Law, where he was a Staff Member of the Fordham Journal of Corporate and Financial Law and the Writing and Research Editor of the Fordham Sports Law Forum, and received his B.A. from the University of Pennsylvania.